Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Biogen : Cuts Guidance Amid Competition From Generics

10/21/2020 | 08:18am EST

By Matt Grossman

Biogen Inc. on Wednesday cut revenue and earnings guidance for the full year as the company said it was facing new competition from generic versions of Tecfidera, a treatment for multiple sclerosis.

The company said it now expects full-year revenue of $13.2 billion to $13.4 billion, down from a previous projection of $13.8 billion to $14.2 billion. It forecast earnings per share of $25.50 to $26.50, compared with an earlier forecast of $32 to $34.

On an adjusted basis, earnings per share will be between $32.50 and $33.50, Biogen projected.

Analysts polled by FactSet had been expecting full-year revenue of $13.76 billion and adjusted earnings per share of $34.43.

Biogen shares climb 0.7% in pre-market trading from a Tuesday close of $267.12.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

10-21-20 0817ET

All news about BIOGEN INC.
11/27BIOGEN : bets on depression drug in $1.5 billion deal with Sage Therapeutics
RE
11/27SAGE THERAPEUTICS : Biogen bets on depression drug in $1.5 bln deal with Sage Th..
RE
11/27BIOGEN : Sage Therapeutics Reach Global Collaboration for Potential Depression a..
DJ
11/27BIOGEN : and Sage Therapeutics Announce Global Collaboration to Develop and Comm..
AQ
11/27BIOGEN : and Sage Therapeutics Announce Global Collaboration to Develop and Comm..
BU
11/27BIOGEN : and Sage Therapeutics Announce Global Collaboration to Develop and Comm..
AQ
11/27Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Com..
GL
11/24INVESTOR ALERT : Law Offices of Howard G. Smith Announces the Filing of a Securi..
BU
11/23THE LAW OFFICES OF FRANK R. CRUZ : Announces the Filing of a Securities Class Ac..
BU
11/23BIIB SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. ..
BU
More news
Financials (USD)
Sales 2020 13 384 M - -
Net income 2020 4 425 M - -
Net Debt 2020 2 478 M - -
P/E ratio 2020 9,00x
Yield 2020 -
Capitalization 37 513 M 37 513 M -
EV / Sales 2020 2,99x
EV / Sales 2021 3,29x
Nbr of Employees 7 400
Free-Float 86,1%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 34
Average target price 288,67 $
Last Close Price 243,78 $
Spread / Highest target 84,6%
Spread / Average Target 18,4%
Spread / Lowest Target -28,2%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & EVP-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.-17.84%37 513
CSL LIMITED11.34%101 913
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.138.48%29 360
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.55.71%13 914
CANSINO BIOLOGICS INC.172.43%9 296
TWIST BIOSCIENCE CORPORATION446.05%5 178